AzTrials
AzTrials

Type 2 DiabetesMiniExNCT04129268

Determining the Minimal Amount of Exercise to Improve Glycaemic Control

A study testing Cycle ergometry exercise at 60% VO2max in people with Type 2 Diabetes, run by Lancaster University at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In 2015, there were 415 million adults worldwide with type II diabetes and by 2040, typeII diabetes will affect one in ten adults worldwide. Type II diabetes reduces quality of life and total lifespan, and two of the best countermeasures to type II diabetes are not drugs, but diet and exercise. Read more about this study

Who is it for?
Ages 18 to 80 years, men onlyHealthy volunteers can take part
Conditions the study is for
Type 2 Diabetes
What is being tested?
Cycle ergometry exercise at 60% VO2max
Could I receive a placebo?
No, everyone receives an active treatment
How many people
21 participants
Where
1 siteUnited Kingdom
Study dates
1 Oct 2019to 29 Sep 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • Men only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Aged 18 years and upwards
  • Capacity to consent to participation
  • Diagnosis of type II diabetes
  • BMI >25
  • Aged 18 - 40
  • Capacity to consent to participation
Show all 10Show fewer
  • BMI >25
  • Aged >60
  • Capacity to consent to participation
  • BMI >25

Who cannot join

  • Patient is aged under 18 years
  • Patient lacks capacity to consent to participation
  • Anything that investigators feel affects the study measurements or safety
  • Cohort 2: 9 young control subjects under the following criteria:
  • Subject is aged under 18 years
  • Subject lacks capacity to consent to participation
Show all 13Show fewer
  • Subject on medication that affects glycaemic control
  • Anything that investigators feel affects the study measurements or safety
  • Cohort 3: 9 older control subjects under the following criteria:
  • Subject is aged under 18 years
  • Subject lacks capacity to consent to participation
  • Subject on medication that affects glycaemic control
  • Anything that investigators feel affects the study measurements or safety

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Royal Lancaster Infirmary

    Lancaster

Other trials in United Kingdom

About this study

Official title: Determining the Minimum Amount of Exercise to Improve Glycaemic Control in Young and Old Overweight Males, and in Patients With Type II Diabetes

In 2015, there were 415 million adults worldwide with type II diabetes and by 2040, typeII diabetes will affect one in ten adults worldwide. Type II diabetes reduces quality of life and total lifespan, and two of the best countermeasures to type II diabetes are not drugs, but diet and exercise. Several studies have investigated the effects of exercise modality (aerobic, resistance, or concurrent) on glycaemic control and the mechanisms of these benefits. However, the minimal 'dose' of exercise required to increase insulin sensitivity and improve glycaemic control has never been established. Secondly, there is a progressive loss of muscle structure and function with age, which is known as sarcopenia. This study will also investigate whether the minimal amount of exercise is influenced by biological age and muscle mass by comparing physiological and biochemical responses in BMI-matched young and old volunteers. This study will therefore provide pilot data on the effect of age on exercise-mediated glycaemic control.

Read the detailed description

Background Information and rationale Overarching aim: The purpose of this study is to identify the minimum number of calories that must be expended to improve the control of blood glucose in young and older overweight males, and in those with type II diabetes.

Why is this important? In 2015, there were 415 million adults worldwide with type II diabetes and by 2040, type II diabetes will affect one in ten adults worldwide. If the minimal volume of exercise to improve glycaemic control can be established, this could increase exercise compliance and population health.

Current knowledge and preliminary data Acute exercise improves glycaemic control by promoting the translocation of the glucose transporter GLUT-4 in an insulin-independent pathway. This mechanism is intact even in patients with type II diabetes. An acute bout of exercise for ~70 mins at 65% VO2max (energy expenditure of 350kcal) improves insulin sensitivity by ~15% 1h after exercise, and ~30% the day following exercise in obese adults. This improved insulin sensitivity is also associated with a 17% reduction in circulating free fatty acids, which chronically might benefit both type II diabetes and cardiovascular disease - a major secondary complication of type II diabetes. Several studies have investigated the effects of exercise modality (aerobic, resistance, or concurrent) on glycaemic control and the mechanisms of these benefits (8). However, the minimal 'dose' of exercise required to increase insulin sensitivity and improve glycaemic control has never been established. Secondly, there is a progressive loss of muscle structure and function with age, which is known as sarcopenia. This study will also investigate whether the minimal amount of exercise is influenced by biological age and muscle mass by comparing physiological and biochemical responses in BMI-matched young and old volunteers. Establishing the dose-response relationship for exercise and glycaemic control. It is important to establish the optimal dose-response relationship for exercise and glycaemic control in order to maximise the health benefits and minimize side-effects of the exercise intervention. Whilst the risks of exercise are low unless undertaking athlete-level training for several years, establishing the minimum exercise required for glycaemic control would improve exercise adherence. Indeed, lower volumes of exercise are easier to maintain than larger volumes, and this has led to the adoption of short-duration exercise strategies for glycaemic control, such as high intensity interval training.

Previous work has shown that an acute bout of cycling expending 350kcal can increase insulin sensitivity by ~30% the day following exercise in obese adults. On this basis, the proposed study will test three levels of kcal expenditure: 1) a 350kcal intervention, which is predicted to increase insulin sensitivity in line with; 2) a 700kcal intervention, to deliver a profound (doubling) stimulus to increase insulin sensitivity; and 3) 175kcal intervention, to examine the efficacy of a halved stimulus on insulin sensitivity. These three intervention points are necessary in order to accurately model the dose response relationship between amount of exercise and insulin sensitivity, which is currently unknown. There will also be a no exercise trial where the same data are collected and used to calculate baseline glycaemic control/insulin sensitivity from which any increase prompted by exercise can be determined. If the minimal volume of exercise to improve glycaemic control can be established, this could increase exercise compliance and population health. This minimal amount of exercise may increase in older subjects where muscle mass and quality is reduced. This study will therefore provide pilot data on the effect of age on exercise-mediated glycaemic control.

Objectives of the study Recruitment and testing will take place throughout the first 15 months of the study, allowing 3 months at the end of the study for data analysis. The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise trials the day before an oral glucose tolerance test (OGTT). An acute bout of 350kcal exercise can improve insulin sensitivity by ~30% the following day; the trials in the proposed study intend to result in: (i) baseline glycaemic control; (ii) small improvements in glycaemic control; (iii) ~30% improvement in glycaemic control; and (iv) large >30% improvement in glycaemic control. The OGTT, continuous glucose monitoring (CGM), measurement of insulin, and FFA will be used to calculate dose response curves in each of these individual variables, where the minimum amount of exercise to improve glycaemic control can be ascertained.

Conditions
Type 2 Diabetes
Being tested
Cycle ergometry exercise at 60% VO2max
Medical subject headings
Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cycle ergometry exercise at 60% VO2maxOther

    Participants visit the lab on four occasions to complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; (iv) or 700kcal exercise (randomised).

Study groups in NCT04129268
Study groupRoleWhat they receive
No exercise controlOtherThe investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT). 350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis.
Receives: Other: Cycle ergometry exercise at 60% VO2max
175kcal Cycle ergometry exercise at 60% VO2maxExperimentalThe investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT). 350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis.
Receives: Other: Cycle ergometry exercise at 60% VO2max
350kcal Cycle ergometry exercise at 60% VO2maxExperimentalThe investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT). 350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis.
Receives: Other: Cycle ergometry exercise at 60% VO2max
700kcal Cycle ergometry exercise at 60% VO2maxExperimentalThe investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT). 350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis.
Receives: Other: Cycle ergometry exercise at 60% VO2max

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Lowering of blood glucose values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities

    The investigators will quantify the lowering of blood glucose values during the OGTT 24h following 175kcal, 350kcal and 700kcal exercise when compared to a no exercise control.

    Measured: over the 8 weeks of participant involvement in study

Secondary outcomes (1)
  1. Lowering of serum insulin values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities

    The investigators will quantify the lowering of serum insulin values during the OGTT 24h following 175kcal, 350kcal and 700kcal exercise when compared to a no exercise control.

    Measured: over the 8 weeks of participant involvement in study

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Oct 2019
  2. Study start1 Oct 2019
  3. Primary completion26 Sep 2022
  4. Study completion29 Sep 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
21 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04129268
Sponsor's protocol ID
248319
Other IDs
19/NW/0066
Acronym
MiniEx
Status last verified
May 2023
First submitted
9 Oct 2019
Last updated
22 May 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Cycle ergometry exercise at 60% VO2max in people with Type 2 Diabetes, run by Lancaster University at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 May 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Lowering of blood glucose values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities (time frame: over the 8 weeks of participant involvement in study). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in